Generic Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett

NEW YORK, October 18, 2017 /PRNewswire/ --

If you want a Stock Review on PSDV, TTPH, CTLT, or LCI then come over to and sign up for your free customized report. On Tuesday, October 18, 2017, US markets saw six out of nine sectors finishing the day in red, two in green, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,623.66, down 0.01%; the Dow Jones Industrial Average edged 0.18% higher to finish at 22,997.44; and the S&P 500 closed at 2,559.36, up 0.07%. This Wednesday morning, looks at the performance of these four Drugs - Generic stocks: pSivida Corp. (NASDAQ: PSDV), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Catalent Inc. (NYSE: CTLT), and Lannett Co. Inc. (NYSE: LCI). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:


On Tuesday, shares in Watertown, Massachusetts headquartered pSivida Corp. recorded a trading volume of 671,482 shares, which was above their three months average volume of 486.20 thousand shares. The stock ended the session 0.83% lower at $1.20. The stock is trading below its 50-day moving average by 0.50%. Moreover, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have a Relative Strength Index (RSI) of 48.90. Visit us today and download your complete report on PSDV for free at: Tetraphase Pharmaceuticals 

Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc.'s stock closed the day 2.56% lower at $6.47 with a total trading volume of 317,369 shares. The Company's shares have advanced 89.18% over the last twelve months and 60.55% since the start of this year. The stock is trading below its 50-day moving average by 2.13%. Additionally, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 41.37.

On October 09th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock at a target price of $13 a share. The complimentary research report on TTPH can be accessed at: Catalent 

Shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 414,276 shares. The stock ended yesterday's trading session 1.02% lower at $41.55. The Company's shares have advanced 15.19% over the previous three months, 77.56% in the past twelve months, and 54.12% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.80% and 25.38%, respectively. Furthermore, shares of Catalent, which provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide, have an RSI of 56.45.

On September 21st, 2017, research firm Morgan Stanley upgraded the Company's stock rating from 'Equal-Weight' to 'Overweight'. Register for free on and download the research report on CTLT at: Lannett 

Philadelphia, Pennsylvania-based Lannett Co. Inc.'s stock finished Tuesday's session 2.32% lower at $23.15 with a total trading volume of 1.41 million shares, which was above their three months average volume of 744.47 thousand shares. The Company's shares have advanced 37.39% in the last month. The stock is trading above its 50-day and 200-day moving averages by 29.37% and 12.69%, respectively. Additionally, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 75.54. Get free access to your research report on LCI at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.